Why I’d follow Neil Woodford and sell this FTSE 100 stock

G A Chester reveals his concerns about the valuation and prospects of a popular FTSE 100 (INDEXFTSE:UKX) stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Veteran fund manager Neil Woodford sold all his shares in AstraZeneca (LSE: AZN) earlier this year. The FTSE 100 pharma giant had previously been one of his core holdings.

There were two reasons behind the sale. He needed to raise capital to meet redemptions from his under-performing funds and he also wanted to increase his exposure to domestically-focused companies like Lloyds and a number of the UK’s house-builders. He reckoned the investment thesis for AstraZeneca was still appealing but that there was even greater upside potential in the stocks he moved into.

Credibility deficit

I’ve been positive on the investment case for AstraZeneca for a good number of years. However, I’ve been reviewing my take on the valuation and prospects of the company in recent months, following the release of its annual results in February.

In the summer of 2014, when fighting off a 5,500p takeover bid from US giant Pfizer, AstraZeneca’s chief executive, Pascal Soriot, made a couple of pledges. He said falling revenues would reverse and in 2017 be back up to the level of 2013 ($25.7bn). This didn’t happen. The actual revenue delivered in 2017 was $22.5bn. City analysts now don’t expect it to surpass the 2013 level until 2020.

The other pledge Soriot made back in 2014 was that the company would be delivering annual revenue in excess of $45bn by 2023. This now looks far-fetched to me and almost certainly another instance of the chief executive over-promising and under-delivering. As a result, he’s built up a sizeable credibility deficit in my book.

Problematic future

In the halcyon days of the first decade of the century, AstraZeneca was consistently making a return on capital employed (ROCE) of a mid-to-high 20s percentage. It even reached above 30% in some years. However, by 2013 it had fallen to below 10% and by 2014 to below 5%. The company made some progress on ROCE in 2015 (7.8%) and 2016 (9%) but 2017 saw the positive trend reverse with it falling back to 6.3%.

My previous optimism about AstraZeneca being able to return to a high ROCE has been further tempered by a two-part blogpost, ‘Pharma’s broken business model,’ by Kelvin Stott, director of R&D portfolio management at Novartis.

Dr Stott addressed the issue of entrenched falling returns on R&D investment and argued that this won’t be overcome by many of pharma’s current strategies, including continuous improvement, new discovery technologies, in-licensing, precision medicine, big data and artificial intelligence. While his work didn’t go uncriticised, I do see AstraZeneca’s future as more problematic than the bull case would have us believe. In particular, I reckon that returns for shareholders are less certain and have more downside risk than I previously thought.

Current valuation

Given my concerns about management under-delivering on its revenue projections, last year’s fall-back in ROCE and the industry-wide problem of falling returns on R&D investment, I don’t believe the company’s current share price and valuation are appealing.

The price is around the 5,500p Pfizer offered four years ago and the valuation is a rich 22 times current-year forecast earnings with a below-Footsie-average dividend yield of 3.9%. Although the shares are down from last month’s high of over 6,000p, I continue to rate the stock a ‘sell’ at the present level.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »